San Diego’s Sorrento Therapeutics May Be First Viable Vaccine for COVID-19
San Diego-based Sorrento Therapeutics recently announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody…